

# Uncovering the [2Fe2S] domain movement in cytochrome *bc*<sub>1</sub> and its implications for energy conversion

Elisabeth Darrouzet\*, Maria Valkova-Valchanova\*, Christopher C. Moser<sup>†</sup>, P. Leslie Dutton<sup>†</sup>, and Fevzi Daldal\*\*

\*Plant Science Institute, Department of Biology, and <sup>†</sup>The Johnson Research Foundation, Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA 19104

Communicated by Elisabeth Gantt, University of Maryland, College Park, MD, February 23, 2000 (received for review December 15, 1999)

In crystals of the key respiratory and photosynthetic electron transfer protein called ubiquinone:cytochrome (cyt) *c* oxidoreductase or cyt *bc*<sub>1</sub>, the extrinsic [2Fe2S] cluster domain of its Fe-S subunit assumes several conformations, suggesting that it may move during catalysis. Herein, using *Rhodobacter capsulatus* mutants that have modifications in the hinge region of this subunit, we were able to reveal this motion kinetically. Thus, the *bc*<sub>1</sub> complex (and possibly the homologous *b<sub>6</sub>f* complex in chloroplasts) employs the [2Fe2S] cluster domain as a device to shuttle electrons from ubiquinone to cyt *c*<sub>1</sub> (or cyt *f*). We demonstrate that this domain movement is essential for cyt *bc*<sub>1</sub> function, because a mutant enzyme with a nonmoving Fe-S subunit has no catalytic activity, and one with a slower movement has lower activity. This motion is apparently designed with a natural frequency slow enough to assure productive Q<sub>o</sub> site charge separation but fast enough not to be rate limiting. These findings add the unprecedented function of intracomplex electron shuttling to large-scale domain motions in proteins and may well provide a target for cyt *bc*<sub>1</sub> antibiotics.

*Rhodobacter capsulatus* | photosynthetic and respiratory electron transfer | mitochondrial complex III | protein domain motion | Rieske Fe-S subunit

When different crystal structures reveal dramatically different protein conformations, large amplitude domain movements are often inferred. However, in only a few cases such as myosin (1), flagellar motor (2), and ATP synthase (3, 4) have such movements been visualized. The cytochrome (cyt) *bc*<sub>1</sub> (or its cyt *b<sub>6</sub>f* counterpart in chloroplasts) is a key component of respiratory and photosynthetic electron transfer chains (5, 6). Recent crystal structures of the mitochondrial cyt *bc*<sub>1</sub> have revealed that the extrinsic [2Fe2S] cluster domain of the Fe-S subunit occupies various locations within this enzyme complex (7–10). It has been observed in either a position proximal to the ubiquinone (QH<sub>2</sub>) oxidation catalytic site (Q<sub>o</sub> position) from which it takes electrons or a position close to cyt *c*<sub>1</sub> subunit (*c*<sub>1</sub> position) to which it donates electrons (Fig. 1). Because of the large distances observed between the electron-donating and electron-accepting cofactors of the cyt *bc*<sub>1</sub> in the different structures, no one of these locations can support sufficiently rapid electron tunneling (11) to meet the observed turnover rates (12, 13) and the specific substrate–product interactions (14) that occur at the QH<sub>2</sub> oxidation site. Thus, an unprecedented intracomplex electron shuttle motion to transfer electrons during catalysis has been suggested (8). However, neither the presumably essential movement nor the electron transfer associated with it has been visualized before this work.

In light-activated energy transduction systems, such as the one provided by the photosynthetic bacterium *R. capsulatus*, a short flash of light (<10- $\mu$ s duration) can activate the photochemical reaction center, thereby inducing oxidation of two equivalents of cyt *c* (*c*<sub>1</sub> and a mixture of *c*<sub>2</sub>/*c*<sub>3</sub>) that are presented to each cyt *bc*<sub>1</sub> in about 50  $\mu$ s (12, 13). The cyt *bc*<sub>1</sub> is then primed to complete

its catalytic cycle (Fig. 2 *Left A* and *B*). Extensive electron paramagnetic resonance (EPR) spectroscopy data establish that the equilibrium position of the reduced [2Fe2S] cluster domain is located at the Q<sub>o</sub> position (14). Both the amount and rate of flash-oxidized cyt *c* reduction depend on the arrival of electrons via the initially reduced [2Fe2S] cluster and, later, from the millisecond oxidation of QH<sub>2</sub> at the Q<sub>o</sub> site (12, 13). Fig. 2 *Left C–H* depicts how the electrons might get from the Q<sub>o</sub> site to cyt *c*<sub>1</sub> if brought about by the movement of the [2Fe2S] cluster domain.


Fig. 2 *Right* also shows the effects of two powerful natural antibiotics, myxothiazol and stigmatellin, that are commonly used in the laboratory to inhibit the Q<sub>o</sub> site reaction in quite different ways. When myxothiazol is present, no QH<sub>2</sub> oxidation occurs, simply because myxothiazol displaces QH<sub>2</sub>. In this case, cyt *c* reduction kinetics suggest that the initially reduced [2Fe2S] cluster can still move from the Q<sub>o</sub> site to the cyt *c*<sub>1</sub> position and contribute to cyt *c* reduction, which is due only partially to their similar redox potentials. However, this electron transfer from the [2Fe2S] cluster to cyt *c*<sub>1</sub> heme, which is now independent of Q<sub>o</sub> site catalysis, has never been observed (Fig. 2 *Right Top C* and *D*). Thus, if the [2Fe2S] domain moves as proposed, it must occur on a time scale so as to be hidden within the 50- $\mu$ s envelope required to activate the entire system. When stigmatellin is added, the [2Fe2S] cluster domain is trapped in the Q<sub>o</sub> position, as evidenced by EPR (15), crystallographic (8), and reconstitution (16) data. Under these conditions, no electron transfer takes place from the [2Fe2S] cluster to cyt *c*<sub>1</sub> heme, leaving the cyt *c* complement fully oxidized (Fig. 2 *Right Middle C* and *D*). A critical test of the model would be to devise ways to impede the movement sufficient enough to bring it out of the 50- $\mu$ s envelope but not to create a situation as encountered with stigmatellin, where it is stopped altogether. Only then will the reduction of the flash-oxidized cyt *c* visibly depend on the rate of this movement and be strictly controlled by it in the presence of myxothiazol, as shown in Fig. 2 *Right Bottom C* and *D*.

Comparison of various crystallographic data (7–10) indicates that movement of the [2Fe2S] cluster domain would require conformational changes of the linker region encompassing amino acid residues 67–73 in the bovine sequence (corresponding to 43–49 in *R. capsulatus* numbering) and connecting its fixed hydrophobic anchor and extrinsic carboxyl-terminal portions (Fig. 1). We considered that this putative hinge region might therefore be vulnerable to mutations that could obstruct this mobility. Herein, using *R. capsulatus* mutants with alanine

Abbreviations: cyt, cytochrome; Q, ubiquinone; QH<sub>2</sub>, ubiquinol; EPR, electron paramagnetic resonance.

\*\*To whom reprint requests should be addressed. E-mail: fdaldal@sas.upenn.edu.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.



**Fig. 1.** Different positions of the Fe-S subunit extrinsic domain and location of the alanine residue insertions on the linker region. The structure of the three catalytic subunits of the bovine heart cyt *bc*<sub>1</sub> as well as a close view of the bovine Fe-S subunit in two different crystal forms (ref. 9; c<sub>1</sub> and intermediate positions) and that of the chicken heart in the presence of stigmatellin (ref. 8; Q<sub>o</sub> position) are shown. The Fe-S subunit is in blue with its flexible linker region encompassing the amino acid residues 67–73 (corresponding to 43–49 in *Rhodobacter capsulatus*) in orange. Cyt *b* and cyt *c*<sub>1</sub> subunits are in gray, and the cofactors hemes *b*<sub>L</sub>, *b*<sub>H</sub>, and *c*<sub>1</sub> and the [2Fe2S] cluster are in red, with part (residues 255–270 in bovine numbering) of the *ef* loop of cyt *b* in green. The Fe-S subunit sequences from a few selected species (*Paracoccus denitrificans*, *Bos taurus*, *Saccharomyces cerevisiae*, *Neurospora crassa*, and *Solanum tuberosum*) aligned with the sequence of *R. capsulatus* between the positions 38 and 53 and the position of the alanine residues insertion site are also shown, with identical residues highlighted in gray.

residue insertions, we were able to reveal this motion kinetically and demonstrate that it is essential for the function of the cyt *bc*<sub>1</sub>.

## Materials and Methods

**Bacterial Strains and Growth Conditions.** *Escherichia coli* or *R. capsulatus* strains were grown as described in ref. 17 in Luria-Bertani broth or mineral-peptone-yeast-extract enriched medium, respectively, and in the presence of appropriate antibiotics. Respiratory or photosynthetic growth of *R. capsulatus* strains was at 35°C in the dark under semiaerobic conditions or in anaerobiosis under continuous light, respectively. MT-RBC1 is a *bc*<sub>1</sub><sup>-</sup> strain in which the chromosomal copy of the *petABC* operon has been deleted and replaced by a gene cartridge conferring resistance to spectinomycin (17). The strain pMTS1/MT-RBC1 corresponds to MT-RBC1 complemented in *trans* with the plasmid pMTS1, which provides resistance to kanamycin and contains a wild-type copy of *petABC*.


**Molecular Genetic Techniques.** Engineering of mutations located in the linker region of the Fe-S subunit was facilitated by the creation of a unique *Mlu*I restriction site in pMTS1 via a silent mutation at its codon Ala-40, yielding plasmid pMTS1-*Mlu*I (E.D., M.V.-V., and F.D., unpublished work). The alanine insertion mutations were created by PCR with an upstream common primer (5'-GTCTTGGGCTCGTAA-3') and the following downstream specific primers: +1Ala, 5'-ATGAACGCGTTCGGCCGACGTCAAGGCGGCGATGGC-ATCGATCTTCG-3'; +2Ala, 5'-ATGAACGCGTTCGGCCGACGTCAAGGCGGCGGCGATGGCATCGATCTTCG-3'; +3Ala, 5'-ATGAACGCGTTCGGCCGACGTCAAGGCGGCGGCGGCGATGGCATCGATCTTCG-3'. The *Mlu*I-

*Apa*LI fragment containing the mutation thus generated was then exchanged with its wild-type counterpart in pMTS1-*Mlu*I, and the newly constructed plasmids were introduced into MT-RBC1 via triparental crosses (17). In all cases, the presence of the desired mutation and absence of any additional mutation on the insert thus exchanged was confirmed by DNA sequencing.

**Biochemical and Biophysical Techniques.** Chromatophore membrane preparation, protein determination, and 2,3-dimethoxy-5-methyl-6-decyl-1,4-benzohydroquinone:cyt *c* reductase assays were performed as described (17). SDS/PAGE was performed by using an acrylamide concentration of 15% (wt/vol), and gels were stained with Coomassie blue. Immunoblot analyses were performed as described (17), with monoclonal or polyclonal antibodies specific for *R. capsulatus* cyt *bc*<sub>1</sub>, which was purified as described (18). Proteolysis experiments with thermolysin were done at room temperature in 50 mM Tris-HCl (pH 8.0) containing 100 mM NaCl, 0.01% dodecyl maltoside, and 20 μM stigmatellin, when specified (M.V.-V., E.D., C. R. Moomaw, C. A. Slaughter, and F.D., unpublished work). Aliquots were analyzed by immunoblotting with polyclonal antibodies against the Fe-S protein of *R. capsulatus*.

Light-induced, single-turnover, time-resolved kinetics were performed as described (19) by using chromatophore membranes and a single wavelength spectrophotometer (Biomedical Instrumentation Group, University of Pennsylvania) in the presence of 2.5 μM valinomycin, *N*-ethyl-dibenzopyrazine ethyl sulfate, *N*-methyl-dibenzopyrazine methyl sulfate, 2,3,5,6-tetramethyl-1,4-phenylenediamine, and 2-hydroxy-1,4-naphthoquinone. Transient cyt *c* reduction kinetics initiated by a short

## Uninhibited State



**Fig. 2.** Proposed intracomplex electron shuttle mechanism in *cyt bc<sub>1</sub>*. (Left) Schematic representations of the different steps of electron transfer (A, B, D, F, and H) and movement (C, E, and G) in the uninhibited *cyt bc<sub>1</sub>*. The [2Fe<sub>2</sub>S] cluster domain, the *cyt c* complement (*c*<sub>1</sub> + *c*<sub>γ</sub>/*c*<sub>2</sub>) and the Q<sub>o</sub> site are shown as a brown ellipsoid, orange rectangle, and tan square, respectively. Black dots represent electrons located on the [2Fe<sub>2</sub>S] cluster and the *cyt c* heme complement before flash oxidation (A). Arrows refer to electron transfers between cofactors and movement of the [2Fe<sub>2</sub>S] cluster domain between its Q<sub>o</sub> and *c*<sub>1</sub> positions. (Insets) Kinetics of *cyt c* oxidation (downward deflection) and *cyt c* reduction (upward deflection). The dotted parts of the traces in D, F, and H indicate the predicted unresolved fast phase. On flash activation of the reaction center and oxidation of the *cyt c* complement (B), the [2Fe<sub>2</sub>S] cluster domain is proposed to move from its Q<sub>o</sub> to *c*<sub>1</sub> position (C), transfer an electron to *cyt c*<sub>1</sub> of the *cyt c* complement (D), and return to the Q<sub>o</sub> position (E). Then, QH<sub>2</sub> is oxidized to ubiquinone (Q); one electron is transferred to the [2Fe<sub>2</sub>S] cluster; and the other is transferred to the low potential *cyt b* chain (F). The [2Fe<sub>2</sub>S] cluster domain moves back to the *c*<sub>1</sub> position (G) where it transfers another electron (H). (Right) Representation of the steps C (movement) and D (electron transfer) shown in Left in inhibited states. In the presence of the Q<sub>o</sub> site inhibitor myxothiazol (Top), normal movement of the [2Fe<sub>2</sub>S] cluster domain will yield partial reduction of the *cyt c* complement with an unresolved fast phase (blue traces). In the presence of stigmatellin or in a mutant locking the [2Fe<sub>2</sub>S] cluster domain in Q<sub>o</sub> position (Middle), the *cyt c* complement should remain completely oxidized (red traces), whereas in a mutant slowing the movement (Bottom), this fast phase should be time-resolved (blue traces).

saturation flash (8 μs) from a xenon lamp were followed at 550–540 nm, and *cyt b* reduction was followed in the presence of antimycin at 560–570 nm. The concentrations of antimycin, myxothiazol, and stigmatellin used were 5, 5, and 1 μM, respectively, and the ambient potential was poised at 100, 200, or 400 mV as indicated.

Oxidative titrations of the Fe-S subunit [2Fe<sub>2</sub>S] cluster in chromatophore membranes were conducted potentiometrically according to Dutton (20) in the presence of 100 μM tetrachloroquinone, 2,3,5,6-tetramethyl-1,4-phenylenediamine, 1,2-naphthoquinone-4-sulfonate, 1,2-naphthoquinone, *N*-ethyl-dibenzopyrazine ethyl sulfate, and *N*-methyl-dibenzopyrazine methyl sulfate, and in the presence of 100 μM stigmatellin or 300 μM myxothiazol when indicated. EPR spectroscopy of these samples was performed as described (21) by using a Bruker

(Billerica, MA) ESP-300E, equipped with an Oxford Instruments (Oxon, England) ESR-9 helium cryostat, under the following conditions: sample temperature, 20 K; microwave power, 2 mW; modulation amplitude, 20.243 G; modulation frequency, 100 kHz; microwave frequency, 9.45 GHz.

**Chemicals.** All chemicals were as described (22).

## Results and Discussion

**The Alanine Insertion Mutants and Their Initial Characterization.** In an attempt to interfere with the function of the Fe-S subunit hinge region (corresponding to residues 43–49 in *R. capsulatus*), mutants with insertions of one (+1Ala), two (+2Ala), or three (+3Ala) alanine residues were engineered between position 46 and 47 (corresponding to residues 70 and 71 in bovine number-



**Table 1. Characteristics of *R. capsulatus* mutants**

Strains	Ps phenotype*	Steady-state activity, % <sup>†</sup>	Electron transfer QH <sub>2</sub> → cyt <i>c</i> , % <sup>‡</sup>	$E_{m7}$ [2Fe-2S], mV <sup>§</sup>
Wild-type	Ps <sup>+</sup>	100	100	310
+1Ala	Ps <sup>slow</sup>	120	35	370
+2Ala	Ps <sup>-</sup>	5	2	410
+3Ala	Ps <sup>-</sup>	2	2	nd
A46T <sup>  </sup>	Ps <sup>+</sup>	70	65	386
Y147A <sup>   </sup>	Ps <sup>-</sup>	13	6	310

\*Ps<sup>+</sup> and Ps<sup>-</sup> indicate photosynthetic competence and incompetence, respectively.

<sup>†</sup>Steady-state *bc*<sub>1</sub> complex activity was determined by measuring the 2,3-dimethoxy-5-methyl-6-decyl-1,4-benzohydroquinone:cyt *c* reductase activity (17) and is expressed as a percentage of the wild-type activity, which was, in this particular instance, 3.4 μmol cyt *c* reduced min<sup>-1</sup>·mg of membrane protein<sup>-1</sup>.

<sup>‡</sup>QH<sub>2</sub> to cyt *c* electron transfer rates were determined by recording cyt *c* rereduction kinetics at 550–540 nm and fitting them to a single exponential equation (22). The rates are expressed as a percentage of the wild-type rate, which was 300 s<sup>-1</sup>, and reflect single turnover *bc*<sub>1</sub> complex activity. Note that under these conditions, the electron transfer activities from QH<sub>2</sub> → cyt *b* are not significantly different than those from QH<sub>2</sub> → cyt *c* shown here.


<sup>§</sup>The  $E_{m7}$  values were obtained after fitting the amplitude of the EPR *g*<sub>x</sub> signal during potentiometric titration of the [2Fe-2S] cluster as described in *Materials and Methods*. nd, not determined.

<sup>||</sup>A 46 T mutation is located in the Fe-S subunit, and the data are taken from ref. 21.

<sup>|||</sup>Y147A mutation is located in cyt *b* subunit, and the data are taken from ref. 23.

ing; Fig. 1). These mutants properly assembled their cyt *bc*<sub>1</sub>, as shown by immunoblot analyses of the subunits and spectroscopic quantification of their cofactors (*b*- and *c*-type hemes, [2Fe2S] cluster). The [2Fe2S] cluster–Q<sub>o</sub> site interactions of the mutants were normal, and their [2Fe2S] cluster domains were located in the Q<sub>o</sub> position when reduced, as indicated by the position and lines shapes of their EPR *g*<sub>x</sub> signals (14) in the absence and presence of stigmatellin (data not shown). However, the +2Ala and +3Ala mutants were unable to grow, and the +1Ala mutant grew poorly under photosynthetic growth conditions. This finding indicated a cyt *bc*<sub>1</sub> defect, because in phototrophic bacteria like *R. capsulatus*, this enzyme is required for cyclic electron transport. In agreement with these results, the cyt *bc*<sub>1</sub> of the +1Ala mutant was poorly functional, and the cyt *bc*<sub>1</sub> of the +2Ala or +3Ala mutants was nonfunctional as revealed by their single turnover activities (Table 1). Surprisingly, the steady-state activity of the +1Ala mutant was abnormally high in detergent-dispersed membranes.

**The +2Ala Mutant Contains a Nonmoving Fe-S Subunit.** Further insights toward the effects of the alanine insertion mutations were gained by analyzing their cyt *c* reduction kinetics in the presence of the Q<sub>o</sub> site inhibitors stigmatellin and myxothiazol. In the case of the +2Ala (Fig. 3B) and +3Ala (data not shown) mutants, cyt *c* reduction kinetics without inhibitor or with myxothiazol or stigmatellin were almost identical to those observed with a stigmatellin-inhibited native enzyme (Fig. 3A). Thus, this absence of electron transfer from the [2Fe2S] cluster to cyt *c*<sub>1</sub> heme, especially in the presence of myxothiazol, under which conditions this event is independent of Q<sub>o</sub> site catalysis, suggested that in these mutants the [2Fe2S] cluster domain did not move during the 100-ms time scale of the measurements. It is noteworthy that these mutants do not resemble the Q<sub>o</sub> site-inactive mutants such as Y147A (Table 1) (23). The latter mutants behaved even in the absence of any inhibitor as if they had already been inhibited by myxothiazol, but they could still transfer electrons from the [2Fe2S] cluster to cyt *c*<sub>1</sub> heme as




**Fig. 3.** Flash-oxidized cyt *c* reduction kinetics in wild type, +2Ala, and +1Ala mutants and Q<sub>o</sub> site-defective mutant Y147A. The traces obtained with no inhibitor (black), myxothiazol (blue), or stigmatellin (red) with wild type (A), +2Ala mutant (B), +1Ala mutant (C), and Y147A (D) are shown. The ambient redox potential was poised at 100 mV at pH 7.0 such that the Q pool contained substrate QH<sub>2</sub> or at 200 mV for Y147A. Transient kinetics of the flash-induced oxidation and reduction of the cyt *c* complement were followed at 550–540 nm. The concentrations of myxothiazol and stigmatellin were 5 and 1 μM, respectively, for full inhibition. In C, the traces obtained with myxothiazol at pH 9.0 (light blue), under which conditions a lower [2Fe2S] cluster redox midpoint potential contributes, as expected, to a more prominent reduction of cyt *c*, are also shown.

indicated by their cyt *c* reduction kinetics in the presence of stigmatellin (Fig. 3D).

Additional support for the suggestion that the addition of two alanine residues to the hinge region of the Fe-S subunit has locked its extrinsic domain in the Q<sub>o</sub> position included the presence of a higher amount of Q trapped in the Q<sub>o</sub> site of the purified +2Ala mutant cyt *bc*<sub>1</sub> (EPR spectra not shown) and a higher  $E_m$  of the [2Fe2S] cluster ( $\Delta E_m = +100$  mV; Table 1). These indicate a stronger interaction of the [2Fe2S] cluster domain with the Q<sub>o</sub> site, of the kind observed in the presence of stigmatellin. Furthermore, the +2Ala mutant Fe-S subunit showed resistance to thermolysin-mediated, conformation-sensitive proteolysis (ref. 24 and M.V.-V., E.D., C. R. Moomaw, C. A. Slaughter, and F.D., unpublished work) that matched that observed with the native cyt *bc*<sub>1</sub> in the presence of stigmatellin (Fig. 4). This resistance contrasts with the uninhibited native cyt *bc*<sub>1</sub>, which is readily proteolysed by thermolysin to release an 18-kDa Fe-S subunit fragment lacking its first 46 amino acid residues. Thus, the conformation of the +2Ala mutant either with or without stigmatellin resembles that of the native Fe-S subunit in the presence of stigmatellin.

**Movement of the Fe-S Subunit Extrinsic Domain Is Required for cyt *bc*<sub>1</sub> Turnover but Not for QH<sub>2</sub> Oxidation at the Q<sub>o</sub> Site.** Light-induced, single-turnover kinetics experiments monitoring cyt *b* reduction in



**Fig. 4.** Thermolysin-mediated proteolysis of purified or chromatophore membranes embedded *R. capsulatus* *cyt bc*<sub>1</sub>. (A) Purified *cyt bc*<sub>1</sub> (0.6 nmol) from the wild type (lanes 1–3) or +2Ala mutant (lanes 4–6) was digested for 1 h with 0.2 nmol of thermolysin in the presence or absence of 20  $\mu$ M stigmatellin. Aliquots were analyzed by immunoblotting with polyclonal antibodies against the Fe-S subunit of *R. capsulatus*. Lane 1, wild type (WT), nondigested; lane 2, wild type + thermolysin; lane 3, wild type + thermolysin + stigmatellin; lane 4, +2Ala mutant nondigested; lane 5, +2Ala mutant + thermolysin; lane 6, +2Ala mutant + thermolysin + stigmatellin; lane 7, 18-kDa fragment of the Fe-S subunit as a control (19). (B) Chromatophore membranes (650  $\mu$ g) from the wild type, +1Ala mutant, or +2Ala mutant were digested for 1 h with 2 nmol thermolysin in the presence or absence of 20  $\mu$ M stigmatellin. Aliquots were analyzed as described for A; the immunoblot was scanned, and the percentage of the 18-kDa fragment of the Fe-S subunit was calculated and plotted as a bar graph from left to right as wild type + thermolysin, wild type + thermolysin + stigmatellin, +1Ala mutant + thermolysin, +1Ala mutant + thermolysin + stigmatellin, +2Ala mutant + thermolysin, and +2Ala mutant + thermolysin + stigmatellin.

the presence of antimycin and performed at 400 mV (a redox potential at which the [2Fe2S] is initially oxidized) revealed that transient *cyt b* reduction kinetics observed with the +2Ala mutant were similar to those seen with a wild-type strain (QH<sub>2</sub> to *cyt b* about 50 s<sup>-1</sup>; data not shown). Therefore, the absence of the Fe-S subunit extrinsic domain movement does not prevent QH<sub>2</sub> oxidation, even though it abolishes the turnover of the *cyt bc*<sub>1</sub> by impeding the electron shuttling to *cyt c*<sub>1</sub>. This finding further highlights that the concerted electron transfer step is located between the *cyt b* and the Fe-S subunit of the *cyt bc*<sub>1</sub>.

**Visualizing Electron Transfer from the [2Fe2S] Cluster to *cyt c*<sub>1</sub> Heme with the +1Ala Mutant.** Remarkably, in the case of the +1Ala mutant, the *cyt c* reduction kinetics were now slow enough to lie between the wild type (too fast) and the +2Ala mutant (too slow), and hence they were measurable; in the presence and absence of myxothiazol, their half-times were 3 and 10 ms, respectively (Fig. 3C). Moreover, *cyt c* reduction kinetics could be rendered even more obvious by performing the experiments at pH 9.0. Under these conditions, the *E*<sub>m</sub> of the [2Fe2S] cluster (but not that of *cyt c*<sub>1</sub> heme) decreases, thus shifting the redox equilibrium between these two cofactors to favor the reduction of *cyt c*<sub>1</sub> (Fig. 3C, pH 9). Again, diminished cleavage by thermolysin of the +1Ala mutant *cyt bc*<sub>1</sub> (Fig. 4), increased Q content trapped at the Q<sub>o</sub> site of the purified complex (EPR spectra not shown), and increased *E*<sub>m</sub> of the [2Fe2S] cluster ( $\Delta E_m = +60$  mV; Table 1) indicated a more favored Q<sub>o</sub> position for the [2Fe2S] cluster domain.


It could be argued that the slower *cyt c* reduction kinetics observed in the alanine insertion mutants are due to the increased *E*<sub>m</sub> values of their [2Fe2S] clusters thermodynamically displacing the redox equilibrium between the [2Fe2S] cluster and *cyt c*<sub>1</sub> heme. However, other mutants with increased *E*<sub>m</sub> values, such as the Fe-S subunit A46T mutant with *E*<sub>m7</sub> = 386 mV (Table 1), are still functional (21). Further, in the case of the +2Ala mutant, one would expect that in the uninhibited state, the *cyt bc*<sub>1</sub> should still function despite this uphill reaction (25). Moreover, in the presence of myxothiazol, the *E*<sub>m</sub> differences vanish

(E.D., and F.D., unpublished work). Therefore, such thermodynamic equilibrium cannot alone account for the impeded electron transfer observed in the alanine insertion mutants.

A second possibility could be an improper docking of the Fe-S subunit on *cyt c*<sub>1</sub> as a possible consequence of the hinge-region mutations. However, in the mitochondrial *cyt bc*<sub>1</sub> structure in which the Fe-S subunit extrinsic domain is in the *c*<sub>1</sub> position, one of the histidine ligands of the [2Fe2S] cluster (His-161 in bovine numbering) is located close enough to one of the propionates of *cyt c*<sub>1</sub> heme to form a hydrogen bond (8, 9). Electron-tunneling calculations indicate that electron transfer rates between these two cofactors should be extremely fast ( $\ll 1$   $\mu$ s; refs. 11 and 25). Thus, for the electron transfer between the [2Fe2S] cluster and *cyt c*<sub>1</sub> heme to become rate limiting to the level observed in this study (more than several milliseconds), the [2Fe2S] cluster should dock in the alanine insertion mutants at least 5–8 Å away from its native position, which is highly unlikely.

On the other hand, the higher *E*<sub>m</sub> of the [2Fe2S] cluster, the higher Q content trapped in the Q<sub>o</sub> site on purification of the mutant *cyt bc*<sub>1</sub>, and the increased resistance to thermolysin-mediated conformation-sensitive cleavage combine with the slow *cyt c* kinetics to indicate a strongly favored Q<sub>o</sub> position for the extrinsic domain of the Fe-S subunit. Therefore, the slow electron transfer rates observed in these mutants are at least partially due to a hindered movement from the Q<sub>o</sub> site to the *cyt c*<sub>1</sub> position caused by the alanine residue insertions. Further support for this conclusion is provided by the successful isolation of a faster-growing revertant of the +1Ala mutant with a second site suppressor mutation located at position 286 (262 in bovine numbering) of the *ef* loop of *R. capsulatus* *cyt b*. This region represents the most conspicuous physical barrier that needs to be crossed during normal [2Fe2S] cluster domain movement (Fig. 1). Indeed, in this revertant, *cyt c*<sub>1</sub> reduction kinetics in the presence of myxothiazol have a fast unresolved phase (<50  $\mu$ s) exactly like that seen in the wild type (data not shown).

**Implications of the [2Fe2S] Cluster Domain Movement on Energy Conversion.** The [2Fe2S] cluster domain motion on the 1- to 10-ms time scale in the +1Ala mutant may represent an engineering



**Fig. 5.** Functional range of the [2Fe<sub>2</sub>S] cluster domain movement. The time scale of the [2Fe<sub>2</sub>S] cluster domain movement seems poised between two extremes of failure. Slowing the movement, as in the +1Ala mutant, to just less than the normal rate of Q<sub>o</sub> site catalysis  $k_{cat}$  (characteristic turnover time of 600  $\mu$ s) constrains the cyt *bc*<sub>1</sub> turnover and compromises growth. Impeding the motion more drastically with stigmatellin, or as in the +2Ala mutant, blocks cyt *bc*<sub>1</sub> catalysis and photosynthetic growth. Conversely, at faster times, simulations suggest that speeding the motion toward the physical diffusion limits (10 ns) may enable wasteful electron transfer and short circuit the redox-energy conversion mechanism.

boundary at slower times, beyond which the movement begins to interfere significantly with the rate of electron transfer through the cyt *bc*<sub>1</sub> and the rate of physiological growth (Fig. 5). Based on the motion resolved in the +1Ala mutant, it is clear that the movement in the native cyt *bc*<sub>1</sub> must, as proposed, be faster than the 50- $\mu$ s resolution of light-induced kinetics and hence be very much faster

than the  $1,700\text{-s}^{-1} k_{cat}$  of the enzyme (12, 13). Thus, in the native enzyme, movement is required for catalytic activity but is neither rate-limiting nor essential for QH<sub>2</sub> oxidation. Furthermore, our electron transfer simulations indicate that there may be another engineering boundary at faster times in the 1- to 10- $\mu$ s range beyond which the cyt *bc*<sub>1</sub> function may also become impaired (C.C.M., E.D., F.D., and P.L.D., unpublished work). These findings suggest that if the motion becomes too fast, then the system becomes vulnerable to short circuiting of electron transfer in the Q<sub>o</sub> site that inevitably leads to a less efficient energy conversion in the Q cycle mechanism (26).

Large amplitude domain motions therefore represent an effective design to control the flux of electrons inside protein complexes with branched electron transfer pathways. However, this unusual control exposes the cyt *bc*<sub>1</sub> to antibiotics designed to act, not as usual by displacing the substrate from the catalytic sites, but instead on the domain motion. This type of control might be achieved by impeding the helix-random coil conformational change in the [2Fe<sub>2</sub>S] hinge region, which, based on various structures (8–10) and mutants (24, 27), is required for the movement. The intraprotein electron shuttle motion of the Fe-S subunit demonstrated herein can now be explored by using “slow” mutants to analyze how this movement is controlled at the molecular level.

We would like to thank B. R. Gibney and R. E. Sharp for assistance with the EPR and flash kinetics spectroscopy. This work was supported by National Institutes of Health Grants GM 38237 to F.D. and GM 27309 to P.L.D.

- Finer, J. T., Simmons, R. M. & Spudich, J. A. (1994) *Nature (London)* **368**, 113–119.
- De Rosier, D. J. (1998) *Cell* **93**, 17–20.
- Sabbert, D., Engelbrecht, S. & Junge, W. (1996) *Nature (London)* **381**, 623–625.
- Sambongi, Y., Iko, Y., Tanabe, M., Omote, H., Iwamoto-Kihara, A., Ueda, I., Yanagida, T., Wada, Y. & Futai, M. (1999) *Science* **286**, 1722–1724.
- Gray, K. A. & Daldal, F. (1995) in *Anoxygenic Photosynthetic Bacteria*, eds. Blankenship, R. E., Madigan, M. T. & Bauer, C. (Kluwer, Dordrecht, The Netherlands), pp. 747–774.
- Cramer, W., Soriano, G., Ponomarev, M., Huang, D., Zhang, H., Martinez, S. & Smith, J. (1996) *Annu. Rev. Plant Physiol.* **47**, 477–508.
- Xia, D., Yu, C.-A., Kim, H., Xia, J.-Z., Kachurin, A. M., Zhang, L., Yu, L. & Deisenhofer, J. (1997) *Science* **277**, 60–66.
- Zhang, Z., Huang, L., Shulmeister, V. M., Chi, Y.-I., Kim, K. K., Hung, L.-W., Crofts, A. R., Berry, E. A. & Kim, S.-H. (1998) *Nature (London)* **392**, 677–684.
- Iwata, S., Lee, J. W., Okada, K., Lee, J. K., Iwata, M., Rasmussen, B., Link, T. A., Ramaswamy, S. & Jap, B. K. (1998) *Science* **281**, 64–71.
- Kim, H., Xia, D., Yu, C.-A., Xia, J.-Z., Kachurin, A. M., Zhang, L., Yu, L. & Deisenhofer, J. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 8026–8033.
- Moser, C. C., Keske, J. M., Warncke, K., Farid, R. S. & Dutton, P. L. (1992) *Nature (London)* **355**, 796–802.
- Crofts, A. R. & Wang, Z. (1989) *Photosynth. Res.* **22**, 69–87.
- Ding, H., Moser, C. C., Robertson, D., Tokito, M., Daldal, F. & Dutton, P. L. (1995) *Biochemistry* **34**, 15979–15996.
- Ding, H., Robertson, D., Daldal, F. & Dutton, P. L. (1992) *Biochemistry* **31**, 3144–3158.
- Ohnishi, T., Brandt, U. & von Jagow, G. (1988) *Eur. J. Biochem.* **176**, 385–389.
- Valkova-Valchanova, M., Saribas, A. S., Gibney, B. R., Dutton, P. L. & Daldal, F. (1998) *Biochemistry* **37**, 16242–16251.
- Atta-Asafo-Adjei, E. & Daldal, F. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 492–496.
- Robertson, D. E., Ding, H., Chelminski, P. R., Slaughter, C., Hsu, J., Moomaw, C., Tokito, M., Daldal, F. & Dutton, P. L. (1993) *Biochemistry* **32**, 1310–1317.
- Saribas, A. S., Valkova-Valchanova, M., Tokito, M. K., Zhang, Z., Berry, E. A. & Daldal, F. (1998) *Biochemistry* **37**, 8105–8114.
- Dutton, P. L. (1978) *Methods Enzymol.* **54**, 411–435.
- Brasseur, G., Sled, V., Liebl, U., Ohnishi, T. & Daldal, F. (1997) *Biochemistry* **36**, 11685–11696.
- Gray, K., Dutton, P. L. & Daldal, F. (1994) *Biochemistry* **33**, 723–733.
- Saribas, A. S., Ding, H., Dutton, P. L. & Daldal, F. (1995) *Biochemistry* **34**, 16004–16012.
- Darrouzet, E., Valkova-Valchanova, M., Ohnishi, T. & Daldal, F. (1999) *J. Bioenerg. Biomembr.* **31**, 275–288.
- Page, C. C., Moser, C. C., Chen, X. & Dutton P. L. (1999) *Nature (London)* **402**, 47–52.
- Mitchell P. (1975) *FEBS Lett.* **59**, 137–139.
- Tian, H., White, S., Yu, L. & Yu, C.-A. (1999) *J. Biol. Chem.* **274**, 7146–7152.